Market Place
Sourcing Support
Vigil Announces FDA Has Removed Partial Clinical Hold on VG-3927
17 Sep 2024 //
GLOBENEWSWIRE
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
16 Sep 2024 //
GLOBENEWSWIRE
Vigil Receives Positive Opinion From Ema On Orphan Drug Designation For Vgl101
26 Sep 2023 //
PRESS RELEASE
Vigil Presents Vgl101 Complete Phase 1 Data And Phase 2 Ignite Trial Design
11 Sep 2023 //
PRESS RELEASE
Vigil Neuro To Present At 2023 Morgan Stanley Global Healthcare Conference
08 Sep 2023 //
PRESS RELEASE
Vigil Neuroscience Announces Update On Its Small Molecule Trem2 Agonist Program
08 Sep 2023 //
PRESS RELEASE
FDA lifts partial clinical hold on Vigil Neuroscience`s TREM2 antibody
30 Mar 2023 //
ENDPTS
Vigil doses first subject in Phase II ALSP therapy clinical trial
15 Dec 2022 //
CLINICALTRIALSARENA
Vigil Neuroscience Strengthens Board Of Directors
28 Jul 2022 //
PRESS RELEASE
Vigil Neuroscience hits Wall Street with two ex-Amgen TREM2 agonists
14 Jan 2022 //
ENDPTS
Vigil Neuroscience Announces Closing of Initial Public Offering
11 Jan 2022 //
PRESS RELEASE
As three biotechs head to Wall Street, a battered sector braces for a pullback
07 Jan 2022 //
BIOPHARMADIVE
Vigil Neuroscience Announces Pricing of Initial Public Offering
06 Jan 2022 //
PRESS RELEASE
Neurodegenerative disease biotech Vigil Neuroscience sets terms for $112M IPO
03 Jan 2022 //
RENAISSANCECAPITAL
Neurodegenerative disease biotech Vigil Neuroscience files for a $100 m IPO
20 Nov 2021 //
RENAISSANCECAPITAL
Neurodegenerative disease biotech Vigil Neuroscience files for a $100M IPO
19 Nov 2021 //
RENAISSANCECAPITAL
Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study
15 Sep 2021 //
BUSINESSWIRE
Vigil Neuroscience Initiates Enrollment in Study of Patients with ALSP
15 Sep 2021 //
BUSINESSWIRE
Vigil bags $90M to take ex-Amgen CNS assets into the clinic
19 Aug 2021 //
FIERCEBIOTECH
Vigil Neuroscience Completes $90 million Series B to Advance a Pipeline
18 Aug 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.